by TractManager | Oct 22, 2019 | Emerging Technology Report
Viaskin Peanut is an epicutaneously delivered immunotherapy in development for the treatment of peanut allergy. The Viaskin patch contains antigen in dry form, which adheres to a central backing surrounded by an adhesive crown that secures the patch to the skin,...
by TractManager | Oct 17, 2019 | Emerging Technology Report
Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema,...
by TractManager | Oct 17, 2019 | Emerging Technology Report
Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema,...
by TractManager | Oct 15, 2019 | Health Technology Assessment
Health Problem: Lymphedema refers to the swelling that occurs due to the accumulation of protein-rich fluids in tissue experiencing inadequate lymphatic drainage. One of the most common causes of secondary lymphedema are treatments for breast cancer, including...
by TractManager | Oct 11, 2019 | Health Technology Assessment
Health Problem: In the United States, it is estimated that 48 million adults have some type of hearing loss. Hearing loss can be broadly classified as sensorineural (inner ear), conductive (external and middle ear), or mixed. Technology Description: This report...
Recent Comments